G-Quadruplex Assays Using Intrinsic Fluorescent Nucleobase Analogs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assaying the binding of molecules to G-quadruplex DNA structures are inefficient and lack sensitivity, hindering the discovery of potential therapeutics that stabilize these structures and inhibit telomerase activity.
Innovation Solution
A method involving G-quadruplex analogs with intrinsic fluorescent moieties, such as fluorescent nucleobase analogs, is used to measure changes in fluorescence properties upon binding of candidate compounds, facilitating rapid and sensitive screening for G-quadruplex binding and stabilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional assays (titration-NMR, UV spectroscopy, DNA-polymerase stop-assay) are used to monitor binding of molecules to G-quadruplex-DNA, then structural information can be obtained, but the methods are time-consuming and lack sensitivity for rapid screening
Solution Approach 1:
The patent replaces complex mechanical/chemical assay systems (NMR spectrometers, UV spectroscopy equipment, polymerase enzymes) with a simple fluorescence-based detection system. The intrinsic fluorescent moiety within the G-quadruplex analog emits fluorescence that can be directly measured using standard fluorescence instruments, eliminating the need for time-consuming NMR titrations or enzymatic stop-assays while maintaining measurement precision for binding affinity.
Solution Approach 2:
The G-quadruplex analog contains an intrinsic fluorescent moiety that serves as its own probe for binding detection. The fluorescent moiety is integrated into the G-quadruplex structure itself, allowing the complex to self-indicate binding events through fluorescence property changes, eliminating the need for external probes or complex assay mechanisms.
2Measurement precision
If fluorescent nucleobase analogs are incorporated into G-quadruplex analogs to enable sensitive detection, then measurement sensitivity is improved, but the complexity of preparing and characterizing the analogs increases
Solution Approach 1:
The patent uses fluorescent nucleobase analogs that are structural copies of natural guanine bases. These analogs replicate the essential function of guanine in forming G-quadruplex structures while providing an additional fluorescent property for detection. The analogs are designed to be incorporated into the DNA sequence using standard oligonucleotide synthesis methods, avoiding the need for complex custom protein engineering or sophisticated labeling procedures.
3Productivity
If compounds are screened for G-quadruplex binding activity, then potential telomerase inhibitors can be identified, but cytotoxicity of candidate compounds must be managed
Solution Approach 1:
The G-quadruplex analog with intrinsic fluorescent moiety acts as an intermediary model system that selectively interacts with potential telomerase inhibitors. By measuring binding affinity to this simplified G-quadruplex model, the patent can identify compounds that stabilize G-quadruplex structures before testing them in complex cellular assays, allowing for early detection of cytotoxic effects and optimization of safe dosing ranges.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables effective screening of large libraries of compounds for their ability to bind and stabilize G-quadruplex structures, potentially identifying telomerase inhibitors with reduced cytotoxicity and improved therapeutic potential.
Implementation Method 1
measuring a difference in a fluorescence property of said G-quadruplex analog
Data Source
AI summary
The present invention provides methods for assaying binding of compounds to G-quadruplex structures. Also provided are methods for screening candidate compounds for use as modulators of G-quadruplex activity, and methods for screening candidate compounds for telomerase inhibitory activity. The invention further provides novel compounds useful in the assays of the invention.